Acute sensorineural hearing loss: Furosemide ototoxicity revisited

Hospital Pharmacy

Volumn 43, Issue 12, 2008, Pages

  Baldwin, Kathleen A ^a   Budzinski, Cynthia E ^a   Shapiro, Craig J ^b  

^a Baptist Medical Center   (United States)

^b Nephrology Associates of NE Florida ^*  (United States)

Author keywords

Acute sensorineural hearing loss; Etiology; Furosemide; Ototoxicity; Risk factors

Indexed keywords

FUROSEMIDE; INFUSION FLUID; SODIUM POTASSIUM CHLORIDE COTRANSPORTER;

ADULT; ARTICLE; BOLUS INJECTION; CASE REPORT; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; DISEASE COURSE; DIURETIC THERAPY; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOALBUMINEMIA; OTOTOXICITY; PATHOGENESIS; PERCEPTION DEAFNESS; RESPIRATORY DISTRESS; RISK FACTOR; SEPTIC SHOCK; TREATMENT OUTCOME;

EID: 58149289847     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4312-982     Document Type: Article

References (31)

1. Rybak LP. Ototoxicity of loop diuretics. Otolarynol Clin North Am. 1993;26(5):829-844.
2. Flagella M, Clarke LL, Miller ML, et al. Mice lacking the basolateral Na-K-2Cl cotransporter have impaired epithelial chloride secretion and are profoundly deaf. J Biol Chem. 1999;274(38):26946-26955.
3. Delpire E, Lu J, England R, Dull C, Thorne T. Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl co-transporter. Nat Genet. 1999;22(2):192-195.
4. Ding D, McFadden SL, Woo JM, Salvi RJ. Ethacrynic acid rapidly and selectively abolishes blood flow in vessels supplying the lateral wall of the cochlea. Hear Res. 2002;173(1-2):1-9.
5. Arnold W, Nadol JB Jr, Weidauer H. Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics. Acta Otolaryngol. 1981;91(5-6):399-414.
6. Gallagher KL, Jones JK. Furosemide-induced ototoxicity. Ann Intern Med. 1979;91(5):744-745.
7. Schwartz GN, David DS, Riggio RR, Stenzel KH, Rubin AL. Ototoxicity induced by furosemide. N Engl J Med. 1970;282(25):1413-1414.
8. Heidland A, Wigand ME. The effect of furosemide at high doses on auditory sensitivity in patients with uremia. Klin Wschr. 1970;48:1052-1056.
9. Rybak, LP. Furosemide ototoxicity: clinical and experimental aspects. Laryngoscope. 1985;9(pt 2)(suppl 38):1-14.
10. Brown CG, Ogg CS, Cameron JS, Bewick M. High dose frusemide in acute reversible intrinsic renal failure. Scott Med J. 1974;19(suppl 1):35-39.
11. Rupp W. Pharmacokinetic and pharmacodynamics of Lasix. Scott Med J. 1974;19(suppl 1):5-13.
12. van Olden RW, van Meyel JJ, Gerlag PG. Acute and long-term effects of therapy with high-dose furosemide in chronic hemodialysis patients. Am J Nephrol. 1992;12(5):351-356.
13. Göttl KH, Roesch A, Klinke R. Quantitative evaluation of ototoxic side effects of furosemide, piretanide, bumetanide, azosemide, and ozolinone in the cat - a new approach to the problem of ototoxicity. Naunyn Schmiedebergs Arch Pharmacol. 1985;331(2-3):275-282.
14. Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28(2):376-382.
15. Risler T, Schwab A, Kramer B, Braun N, Erley C. Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure. Cardiology. 1994;84(suppl 2):155-161.
16. Tilstone WJ, Fine A. Furosemide kinetics in renal failure. Clin Pharmacol Thera. 1978;23(6):644-650.
17. Beermann B, Dalén E, Lindström B. Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther. 1977;22(1):70-78
18. Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ. 2006;333(7565):420.
19. Chu PL, Wu CC, Hsu CJ, Wang YT, Wu KD. Potential ototoxicity of aluminum in hemodialysis patients. Laryngoscope. 2007;117(1):137-141.
20. Viani A, Carrai M, Pacifici GM. Plasma protein binding of frusemide in liver disease: effect on hypoalbuminaemia and hyperbilirubinaemia. Br J Clin Pharmacol. 1989;28(2):175-178.
21. Seligmann H, Podoshin L, Ben-David J, Fradis M, Goldsher M. Drug-induced tinnitus and other hearing disorders. Drug Saf. 1996;14(3):198-212.
22. Low WK, Toh ST, Wee J, Fook-Chong SM, Wang DY. Sensorineural hearing loss after radiotherapy and chemotherapy: a single, blinded, randomized study. J Clin Oncol. 2006; 24(12):1904-1909.
23. Jung TT, Rhee CK, Lee CS, Park YS, Choi DC. Ototoxicity of salicylate, non-steroidal antiinflammatory drugs, and quinine. Otolaryngol Clin North Am. 1993;26(5):791-810.
24. Ho T, Vrabec JT, Burton AW. Hydrocodone use and sensorineural hearing loss. Pain Physician. 2007;10(3):467-472.
25. Mukherjee B, Shivakumar T. A case of sensorineural deafness following ingestion of sildenafil. J Laryngol Otol. 2007;121(4):395-397.
26. Mahasitthiwat V. A woman with sudden bilateral sensorineural hearing loss after treatment of psoriasis with acitretin. J Med Assoc Thai. 2005; 88(suppl 1):S79-S81.
27. Bates DE, Beaumont SJ, Baylis BW. Ototoxicity induced by gentamicin and furosemide. Ann Pharmacother. 2002; 36(3):446-451.
28. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.
29. Furosemide: drug information. Lexi-Comp [database online]. Hudson, OH: Lexi-Comp, Inc. http://www.uptodate.com/online/content/topic.doPtopicKey= drug_a_k/113157#11. Accessed August 13, 2007.
30. Furosemide. University of Maryland Medical Center Web site. http://www.umm.edu/altmed/drugs/furosemide056500.htm#Administration. Accessed September 4, 2007.
31. Furosemide. Drugdex Version 5.1 [database online]. Greenwood Village, CO: Thomson Micromedex. http://wwwthomsonhc.com/hcs/librarian/ND_T/ HCATIONSHIELDSYNC/A58E5B/ND_PG/PRIH/ND_B/HCS/SBK/2/ND_P/Main/PFPUI/ aILDu92FPY6ZE/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/0011/ ContentSetId/31/SearchTerm/furosemide%20/SearchOption/BeginWith#secN117FC. Accessed September 4, 2007.